This Article Full Text Full Text (PDF) All Versions of this Article: 50/3/459    most recent HYPERTENSIONAHA.107.096966v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Verdecchia, P. Articles by Reboldi, G. Search for Related Content PubMed PubMed Citation Articles by Verdecchia, P. Articles by Reboldi, G. Related Collections Obesity Secondary prevention Risk Factors Type 2 diabetes Glucose intolerance Clinical Studies Epidemiology Related Article

(Hypertension. 2007;50:459.)
© 2007 American Heart Association, Inc.

Editorial Commentaries

New-Onset Diabetes, Antihypertensive Treatment, and Outcome

Paolo Verdecchia; Fabio Angeli; Gianpaolo Reboldi

From the Ospedale "S. Maria della Misericordia" (P.V., F.A.), Struttura Complessa di Cardiologia, Unità di Ricerca Clinica "Cardiologia Preventiva," Perugia, Italy; and the Dipartimento di Medicina Interna (G.R.), Università degli Studi di Perugia, Perugia, Italy.

Correspondence to Paolo Verdecchia, Struttura Complessa di Cardiologia, Unità di Ricerca Clinica, Cardiologia Preventiva, Ospedale "S. Maria della Misericordia," 06132 Perugia, Italy. E-mail verdec@tin.it

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
New-onset diabetes (NOD) confers increased risk for cardiovascular disease and all-cause mortality in different clinical settings.^1,2 In the specific context of hypertensive subjects exposed to the long-term effects of antihypertensive drugs, a study from our group³ and a recent 28-year follow-up study from Sweden⁴ showed a greater risk of major cardiovascular disease in hypertensive subjects who developed NOD than in those who did not. Notably, the yearly incidence of NOD ranged from 1.0% in the Swedish study⁴ to 1.9% in our study.³

This issue of Hypertension hosts a posthoc analysis of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) database, which tested the hypothesis that NOD is a predictor of cardiac morbidity and cardiac and all-cause mortality.⁵ The hypertensive subjects who developed NOD showed a 43% higher risk of cardiac morbidity (ie, a composite of sudden death, myocardial infarction, death associated with revascularization, and congestive heart failure requiring hospitalization) when compared with those who did not develop diabetes.

When the determinants of the composite pool of cardiovascular events were examined separately, NOD was associated with a marginally higher risk of myocardial infarction (hazard ratio [HR]: 1.30; 95% CI: 0.99 to 1.70; P=0.057) and a significantly higher risk of congestive heart failure (HR: 1.41; 95% CI: 1.06 to 1.87; P=0.017). These findings are in full agreement with a recent report from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), in which NOD was associated with a 74% excess risk of congestive heart failure requiring hospitalization.⁶

. . . [Full Text of this Article]

Related Article:

Impact of New-Onset Diabetes Mellitus on Cardiac Outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial Population

Tonje A. Aksnes, Sverre E. Kjeldsen, Morten Rostrup, Per Omvik, Tsushung A. Hua, and Stevo Julius
Hypertension 2007 50: 467-473. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				R. Izzo, G. de Simone, M. Chinali, G. Iaccarino, V. Trimarco, F. Rozza, R. Giudice, B. Trimarco, and N. De Luca Insufficient Control of Blood Pressure and Incident Diabetes Diabetes Care, May 1, 2009; 32(5): 845 - 850. [Abstract] [Full Text] [PDF]

				R. M. Cooper-DeHoff, M. A. Pacanowski, and C. J. Pepine Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J. Am. Coll. Cardiol., February 3, 2009; 53(5 Suppl): S28 - S34. [Abstract] [Full Text] [PDF]

				T. Shafi, L. J. Appel, E. R. Miller III, M. J. Klag, and R. S. Parekh Changes in Serum Potassium Mediate Thiazide-Induced Diabetes Hypertension, December 1, 2008; 52(6): 1022 - 1029. [Abstract] [Full Text] [PDF]